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Some aspects of the pharmacology of oral anticoagulants
The pharmacology of oral anticoagulants ls discussed with particular rejerence to data
of value in the management of therapy. The importance of individual variability in
response and drug interaction is stressed. Other effects of these agents which may
have clinical utility are noted.
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In the twenty-five years sinee the isola-
tion of the hemorrhagie faetor in spoiled
sweet clever," the gradually inereasing
utilization of oral antieoagulants for the
prevention and therapy of thromboembolie
disease has made them one of the most
widely used groups of pharmacologic
agents. This review is restrieted to as-
peets of the pharmaeology of these agents
whieh may be important to their proper
clinieal utilization.
Relation of structure to function
The oral antieoagulants have been di-
vided into four main groups on the basis
of ehemieal strueture (Fig. 1).
Although a number of investigators have
attempted to define the struetural char-
aeteristies neeessary for the produetion of
an antieoagulant effeet, eaeh theory has
been partially invalidated by the diseovery
of exeeptions. Arora and Mathur" have
reeently proposed that antieoagulant ac-
tivity of eoumarins is governed not by in-
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dividual struetural features but by a com-
bination of several: molecular shape, in-
creased aetivity with 6 membered hetero-
eyclic rings with a substituent in position
8 and with a methoxyl rather than a free
hydroxl group. Also important is the dernon-
stration that levorotatory warfarin is seven
times more aetive than its enantiomer.F"
As Hunter and Shepherd'" have pointed
out, the failure to obtain a precise cor-
relation between strueture and antieoagu-
lant aetivity is "not surprising in view of
the influence of small struetural changes
on sueh variables as solubility, rate of ab-
sorption, ease of distribution, degree of
binding by tissues or plasma protein and
rate of detoxieation and excretion."
All eoumarin-type antieoagulants are 4-
hydroxyeoumarins. Mead and associates
have shown that 3-, 5-, 6-, 7-, and 8-hy-
droxyeoumarins are phenolie in nature and
are metabolized in rabbits principally by
direct eonjugation with glueuronic and
sulfuric acids. However, 4-hydroxyeou-
marin differs from its isomers in conju-
gating only with glucuronic acid. It forms
no ethereal sulfates since it is a relatively
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1. Compounds with two coumarin rings: "Dicoumaro1s"
OH R OH Bishydroxycoumarin R=H
m"""·eH-CO"""I I Ethylbiscoumacetate R=COOC2HS~ 0 ~O cf 0 "I-
2. 3-substituted 4-hydroxycoumarins: IMono-coumaro1s"
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3. Cyclic acetals: "Cyclocoumarols"
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4. Indandiones
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Chlorphenylindandione R=~Cl
Fig, 1. Four main groups of oral anticogulants on the basis of chemical structure.
strong acid with a pK of 5.8.98 This differ-
ence may have pharmacologic implica-
tions since almost all other naturally oc-
curring derivatives of coumarin are either
7-hydroxy derivatives or 7-0-ethers, and
the 7-position may be more susceptible to
biologic attack."
Newer agents
A number of reports conceming new
oral anticoagulants have appeared in the
past several years. Most have been newly
synthesized derivatives of 4-hydroxycou-
marirr'" 48, 53, 67 or phenylindandione'": 113,
162 without unique properties or clinical
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utility. The isolation of a complex 4-
phenylcoumarin with anticoagulant and
quinidine-like aetivity from an Indian me-
dicinal plant" is of interest chiefly because
of the rarity of naturally occurring 4-sub-
stituted coumarins.
New compounds of potential interest
have recently been prepared by esterifica-
tion of polyvinyl alcohol with the lactone
of bis 4-hydroxy-3-coumaryl acetie acid;
the product is a copolymer of vinyl alco-
hol and the vinyl ester of pelentanic acid.
Fractions of varying molecular weight and
degree of esterification have been ob-
tained. Anticoagulant activity has been ob-
served in rabbits after oral or intravenous
administration of a fraction of 30,000
molecular weight; fractions of higher
molecular weight were very toxic, After a
single dose, an anticoagulant effect was
observed for as long as 15 days; as with
other coumarin derivatives, onset of a
measurable anticoagulant effect took place
after a lag period of 20 to 24 hours. An
unexpected aspect of these studies was the
discovery that this agent produced a pro-
nounced increase in coagulation time of
whole blood as weIl as prothrombin
time.1 28
Mechanism of action
The keto isomer of 4-hydroxycoumarin
has a elose structural relationship to mena-
dione ( vitamin K~). Substitution of a
methoxy group for the methyl in menadi-
one (2-methyl-1,4 naphthoquinone) con-
verts this synthetic vitamin K into a com-
pound with anticoagulant activity.''" Cou-
marin and related anticoagulants are
thought to act by means of some antago-
nistic effect upon the action of vitamin K.
AIthough originally postulated to be com-
petitive inhibitors of vitamin K, Lowen-
thaI and Macli'arlane'" have presented
data derived from experiments with the
simultaneous administration of warfarin
and moderate doses of vitamin K1 to rats
which they have interpreted as indicating
that the antagonism between these two
agents is neither of the elassical competi-
tive or noncompetitive type. They propose
that the action of an oral anticoagulant
depends upon the irreversible inhibition
of transport of vitamin K1 to its intraceUu-
lar site of action in the liver." With a
much larger dose of vitamin K1 , however,
this inhibition can be surmounted, pos si-
bly because vitamin K can enter the cell
by an aIternate mechanism which cannot
be inhibited by oral anticoagulants." As
to its intracellular site of action, Olson-"
postulates that vitamin K may be necessary
for the derepression of a regulator gene
which controls the synthesis of elotting
factors and that an anticoagulant may in-
terfere with the action of vitamin K on
the repressor substance. There is no evi-
dence in support of any chemical altera-
tion of prothrombin (or other cIotting Iac-
tors) or inhibition of its release or any
increased rate of utilization or degrada-
tion."
None of the oral anticoagulants has a
signincant anticoagulant effect when added
to blood in vitro. When these agents are ad-
ministered to animals or man, the func-
tional aetivities of several cIotting factors
decrease. A decrease in activity of factor
VII is followed sequentially by decreases
in factors IX, X, and II (true prothrom-
bin ). The rate of decrease in functional
activity of these coagulation factors ap-
pe ars to be related to the half-lives of the
individual proteins. After termination of
therapy, these elotting factors return to
normal levels in the same order." All anti-
coagulants produce the same effect. John-
son," who proposes that purffied pro-
thrombin can be converted to factor VII
or factor IX by varying the activators, has
suggested that the actions of oral antico-
agulants on these multiple elotting factors
may be interrelated, possibly representing
minor structural alterations of a single pro-
tein.
Inhibition of thrombosis
The therapeutic value of oral anticoagu-
lants in the prevention of thrombus forma-
tion or inhibition of propagation of pre-
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existing thrombi has been attributed to
their effects in reducing activities of the
above-mentioned clotting factors. In recent
years contradictory data have appeared
concerning a possible additional effect
upon platelet function. Platelets play an
important role in the initiation of throm-
bus formation, particularly in arteries. The
true effect of oral anticoagulant therapy
upon platelets is difficult to assess because
of differences in experimental methods
(some in vitro, others in vivo) , different
animaI species, and measurement of differ-
ing effects ( adhesiveness, aggregation,
thrombus weight, etc.). In man, adequate
doses of bishydroxycoumarin have been
reported to bring ab out a prolongation of
platelet survival and a decrease in platelet
turnover and platelet adhesiveness.vv v"-
161, 186 Inadequate dosage may have the
opposite eflect." Platelet-rich plasma from
anticoagulant-treated patients tested in vi-
tro in the Chandler apparatus shows a sig-
niflcant increase in time required for plate-
let aggregation." However, when electri-
cally induced thrombi are produced in
hamster cheek pouches, oral anticoagulants
suppress formation of a fibrin thrombus
but have no significant effect upon the
development of a platelet thrombus."
The data of greatest value to clinicians
in the assessment of the therapeutic utility
of oral anticoagulants are those derived
from well-designed clinical trials. However,
the effects of these agents on both initia-
tion and resolution of thrombi are difficult
to study in man. Numerous investigations
of the antithrombogenic effect of antico-
agulants have been conducted in experi-
mental animals, but, since our knowledge
of the pathogenesis of thrombosis is lim-
ited, results obtained in animals may not
be directly applicable to the management
of human disease. In general, heparin is
more effective than oral anticoagulants in
prevention of the formation of experimen-
tal thrombi. Administration of an adequate
dose of oral anticoagulant is critical for
the demonstration of an antithrombotic
effect; the greater the prolongation of one-
stage prothrombin time, the less the inci-
dence of thrombosis. Thrombus formation
in rats is not reduced by bishydroxycou-
marin unless prothrombin time is twice
normal or greater; in fact, the incidence of
thrombosis in animals receiving a small
dose of drug is higher than that in con-
trols." In experiments with "serum throm-
bosis," the antithrombotic effect of bishy-
droxycoumarin is demonstrable only if the
drug has been administered for one week
or more before thrombosis is produced
(unless very massive doses of drug are
administered ).178 This delay in demonstra-
tion of antithrombotic effect is not present
if thrombosis is produced by vascular in-
jury. 77
If a comparable delay in appearance of
antithrombotic effect is present in human
beings with thrombotic disease, these find-
ings may have implications for clinical
therapy. The thrombus produced by injec-
tion of serum into an occluded venous seg-
ment is similar histologically, and probably
in pathogenesis, to the "stasis" thrombus
seen so frequently in the deep veins of
the leg. Optimal therapy of patients with
deep venous thrombosis may require simul-
taneous administration of heparin and an
oral anticoagulant until the maximum
therapeutic effectiveness of the oral anti-
coagulant has been achieved.
In animals the administration of oral
anticoagulants has produced an increase
in the rate of recanalization of arterial?"
and venous thrombt-", this was not due to
any demonstrable systemic fibrinolytic ac-
tivity.
Absorption
Probably only a small fraction of orally
administered drug is absorbed in the stom-
ach,' since, as organic acids, oral anti-
coagulants are considerably more soluble
in alkaline solutions. The gastric content
of free hydrochloric acid, however, does
not have a detectable influence upon rate
of onset of anticoagulant effect in man.s'
In general, rate and completeness of gas-
trointestinal absorption are not important
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detenninants of rapidity of "prothrombin"
response, since differences in time of onset
of effect vary little when oral and intra-
venous administration are compared, Drug
can usually be detected in plasma within
one to two hours after ingestion. Although
individual drugs are detectable in plasma
at essentially the same time, the peak con-
centration of some agents (e.g., bishy-
droxycoumarin, warfarin) is reached after
aconsiderably Ionger interval than with
other agents (ethylbiscoumacetate, phenin-
dione).176
On the basis of stool content, absorption
is usually complete, An exceptiön is an oc-
casional report of poorabsorption of both
coumarins and indandiones which appears
to be relatedchiefly to errors in eompound-
ing or cdmpressi0n of tablets,123,176 al-
though other factorsmay also be involved.'
Response to two preparations of the same
anticoagulant may differ by as much as
50 per cent.In Bishydroxycoumarin is more
slowly and less completely absorbed when
given as a tablet rather than as a solution
or powder. In vitro tests of the rate of dis-
integration of tablets are not good predic-
tors of response in vivo.':"
Pretreatment of human subjects with
heptabarbital appears to influence absorp-
tion of bishydroxycoumarin. Increased ex-
cretion of bishydroxycoumarin in the stool
persists for several weeks after withdrawal
of the barbiturate.'
The solubility in water of a drug may
also influence its absorption, Warfarin
sodium is75,000 times more soluble than
bishydroxycoumarin in aqueous solutions;
in contrast to bishydroxycoumarin, un-
changed warfarin has not been recovered
from the stool.' Warfarin is the only "oral"
anticoagulant supplied in a form for in-
travenous or intramuscular administration.
Distribution and metabolism
Satisfactory and relatively simple meth-
ods are available for the determination of
the majority of these drugs; most tech-
niques are based on the original method
for determination of bishydroxycoumarin
devised by Axelrod and associates," These
have been used, along with isotopically
labeled compounds, to study relations be-
tween plasma levels, tissue distribution,
and duration of anticoagulant effect.
The duration of anticoagulant effect cor-
relates reasonably weIl with the interval
in which the drug is retained in plasma174
and in liver." On the basis of serial de-
terminations of plasma levels of individual
drugs, Weiner174 has classifled oral anti-
coagulants by rate of fall from the peak
plasma level as rapid (ethylbiscoumace-
tate: 15 to 45 per cent per hour ), inter-
mediate (acenocoumarin, phenindione: 4
to 15 per cent per hour ), slow (bishy-
droxycoumarin, cyclocumarol, warfarin,
phenprocoumon, anisindione, chlorphenin-
dione: 15 to 20 per cent per day ), and
ultraslow (diphenadione: less than 15 per
cent per day). Within moderate dosage
limits, the higher the initial dose the more
rapid the fall in "pro thrombin" activity.
In general, the more rapid the fall in
blood level the more frequently a dose
must be administered in order to maintain
a stable therapeutic effect.
However, the peak in blood level of a
given drug is not directly associated with
the maximum depression of "prothrombin"
activity'" which may occur 12 hours to
three or more days later. In addition, be-
cause of extensive individual variability,
Weiner-?" has not been able to correlate
depression of prothrombin activity with
the concentration of drug in plasma. Re-
cently, however, Nagashima and col-
leagues-" have reported an essentially
linear relationship between intensity of
"prothrombinopenic" response and the
logarithm of the dose of warfarin or its
concentration in human plasma. This ex-
periment should be repeated with another
oral anticoagulant, since warfarin may be
the only oral anticoagulant in which plasma
half-life is independent of dose.'> The
rates of disappearance of bishydroxycou-
marin and ethylbiscoumacetate from plas-
ma decrease as the doses of drug in-
orease.'"!
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Protein binding may also influence rap-
idity of onset and duration of effect. The
extent of protein binding (99 per cent for
bishydroxycoumarin, 97 per cent for war-
farin, 90 per cent for ethylbiscoumacetate)
roughly paralleIs the biologie half-life and
duration of prothrombinopenic effect. 123
Since at any given time less of the latter
drug is bound, the considerably higher con-
centration of free drug may play a role in
its comparatively rapid onset of effect. As
will be discussed later, other agents which
alter protein binding have a significant in-
fluence upon anticoagulant effect. The
strongest and greatest percentage of bind-
ing is to albumin.!" O'Reilly and asso-
ciates-"- 123 have proposed that the high
degree of nonelectrostatic binding of war-
farin to albumin and its nonpolar character
account for the sustained levels of this
drug in plasma, the absence of urinary
loss, and its small volume of distribution.
Uptake of drug by erythrocytes is vari-
able, being about 20 per cent for bishy-
droxycoumarin and phenindione (rabbit );"
9 to 18 per cent for ethylbiscoumacetate
(rat),69 and less than 1 per cent for war"
farin (man).123 Warfarin is not detectable
in the cerebrospinal fluid (rabbit). 73 Bis-
hydroxycoumarin and other oral anticoagu-
lants cross the placenta, reaching con-
centrations in the plasma of the fetus al-
most comparable to those of the mother.>"
These agents appear in breast milk in
sufficient concentration to induce signifi-
cant depression of prothrombin activity.l'"
The majority of drug is distributed be-
tween plasma and liver'": 30 with lesser
amounts in kidney and intestinal tract.
The rate of elimination follows the kinetics
of a first-order reaction, probably reflect-
ing the rate of metabolie transformation.
When C14-labeled bishydroxycoumarin is
administered to rats," most of the radio-
activity is detectable in the feces within
five days. Only a small amount appears in
the urine. However, if the bile duct is
occ1uded, the major portion of radioactivity
appears in the urine. In other species'": 85,
106 greater amounts of radioactivity normal-
ly appear in the urine, presumably through
reabsorption from the intestinal tract after
biliary excretion. The metabolie products
of oral anticoagulants excreted in urine
have not been fully identifled, The only
anticoagulant excreted unaltered in the
urine in significant amounts is acenocou-
marin.':" Metabolites of several coumarin
derivatives with hydroxyl groups in the
6-, 7-, or 8-positions have been described.
120, 130 The 6-, 7-, and 8-hydroxy metabolites
of warfarin are more polar and bind less
weIl to albumin, probably determining their
absence in plasma and presence in urine.F"
No metabolie product of a coumarin or
indandione has been shown to have anti-
coagulant activity.
A metabolie product of phenindione im-
parts a red color to alkaline human urine";
this color has resulted in mistaken diag-
noses of hematuria. The red color in the
urine disappears when acid is added.
Structurally related indandiones have been
used as industrial dyes. Diphenadione is
yellow in alkaline solution, thereby cre-
ating no problems in misinterpretation of
the color of the urine.
Administration of vitamin K does not
alter metabolie transformation of bishy-
droxycoumarin but does appear to accele-
rate the rate of disappearance of labeled
bishydroxycoumarin from the Iiver."
Variability
One of the major problems in the c1ear
definition of the pharmacologic properties
of oral anticoagulants is a marked vari-
ability in responsiveness: between species,
between individuals, and in the same indi-
vidual under differing conditions, Species
differences are so marked that considerable
caution is necessary in extrapolation of
effects in one or even several types of
animals to man.'?" There are marked inter-
individual differences in the rate of me-
tabolism of a given drug in man. More than
threefold differences in rates of disap-
pearance of bishydroxycoumarin and war-
farin from plasma have been reported.'- 176,
177 Daily maintenance dos es may vary by
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as much as tenfold. Many other elements
such as nutritional state, vitamin K in-
take, age, sex, rate of hepatic synthesis
of clotting factors, etc., may be of even
greater importance. Marked sensitivity or
resistance to oral anticoagulants appears,
in rare instances, to be related to genetic
factors.' Whether less marked interindi-
vidual variability also has some genetic
determinants has not yet been defined.
O'Reilly and Aggeler1 21 have described a
family showing hereditary resistance to
warfarm. The average daily dose of war-
farin to maintain prothrombin time in a
therapeutic range was 49 standard devia-
tions from the mean. The same subject
needed only one-half to one-fifth the usual
dose of vitamin K1 to reverse the antico-
agulant effect. Six of eight members of
the patient's family were also resistant
to the effects of warfarin.
Although the administration of a single
dose of one of these drugs to a healthy
individual on separate occasions brings
about a reproducible plasma concentration
of drug at a given interval, the presence
of certain diseases is associated with con-
siderable intraindividual variation. The in-
fluence of systemic disease upon dose
requirements appears to be related chiefly
to changes in hepatic function which in-
fluence rates of synthesis of critical clotting
factors. No major change in activity of
drug-metabolizing enzymes'" or in the
metabolism of the anticoagulant" have
been demonstrated under these circum-
stances. Changes in gastrointestinal function
which bring about a decrease in intake
or absorption of vitamin K or of orally
administered anticoagulant can also alter
response to a given dose, Since, with the
exception of acenocoumarin, anticoagulants
are not excreted unaltered in sigmficant
amounts by the kidney, it is unlikely that
decreased renal excretion is responsible
for the increased sensitivity of patients
with ehrenie renal disease to these drugs.
A more likely explanation for the increased
incidence of hemorrhagic complications in
these patients is the presence of multiple
other hemostatic abnormalities secondary
to the renal disease itself.
Drug interaction: Effect on
intraindividual variability in response
Tolerance to repeated doses of an anti-
coagulant does not occur except under cir-
cumstances in which other pharmacologic
agents have brought ab out a change in
activity of drug-metabolizing enzymes or
some other form of drug interaction.':"
In recent years a multiplicity of agents
having an effect on anticoagulant dosage
have received attention because of the
significant effect they may have upon
management of therapy. The various
mechanisms through which drugs interact
ineIude: altered intestinal absorption,
changes in transport (protein binding ),
altered metabolism of drug or its antago-
nist, effects upon receptor site, altered
excretion, and chelation. To date, no evi-
dence for the latter two mechanisms in
interactions of drugs with oral anticoagu-
lants has been presented.
The chief drug interaction inHuencing
intestinal absorption is the indirect one in
which various intestinal antibiotics may
influence synthesis or absorption of vita-
min K1 , Iessening the continuous stimulus
by vitamin K1 of production of eIotting
factors and thus increasing the sensitivity
of the individual to a given dose of oral
anticoagulant.
Several drugs are thought to decrease
dosage requirements of anticoagulant by
displacing the anticoagulant from its bind-
ing site or by preventing initial binding to
protein, thus increasing the concentration
of free anticoagulant in plasma and the
amount of drug present at its receptor
site. Phenylbutazone" appears to act
through competitive inhibition while eIo-
fibrate functions by way of noncompetitive
inhibition.116, 1 59 Salicylares mayaiso in-
fluence anticoagulant dosage in this man-
ner, although they have been shown to
have an intrinsic anticoagulant effect as
well.": 33, 55, 152 Oxyphenbutazone'" and
phenyramidol"- 156 also decrease anticoagu-
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lant requirements, presumably by inhibi-
tion of activity of hepatic microsomal drug-
metabolizing enzymes; oxyphenbutazone
mayaIso have an effect upon protein bind-
ing of drug.
Other drugs have been reported to po-
tentiate the effect of oral anticoagulants,
but their mechanism of interaction has not
been defined; these incIude n-thyroxine,':"
androgens.v- 143 haloperidol,115 acetamino-
phen," methylphenidate.f quinidine;" and
several monamine oxidase inhibitors
(tranylcypromine and nialamide) .133 I pro-
niazid has no enhancing effect, while the
action of other monamine oxidase inhibi-
tors lies between these extremes.
Many drugs bring about an increase
in the required dose of oral anticoagulant
through induction of increased activity of
hepatic microsomal coumarin-metabolizing
enzymes; those in which cIinical effects
have been described incIude many barbital
derivatives": 45, 71, 135 (phenobarbital, hepta-
barbital, amobarbital), glutethimide,40, 71
chloral hydrate," and griseofulvin.28 Al-
though many other agents are known to
produce drug tolerance by means of this
mechanism (sulfonylureas, meprobamate,
antihistamines, alcohol, caffeine), a cIinical
effect upon anticoagulant requirements has
not yet been described.
On the other hand, several investigators
have recently reported that coumarin de-
rivatives can affect the action of other
drugs. Bishydroxycoumarin potentiates the
effect of diphenylhydantoin." Simultaneous
administration of bishydroxycoumarin and
tolbutamide may result in protracted hypo-
glycemia158; phenindione does not affect
tolbutamide metabolism.82
Recently, Schrogie and associates':" have
reported that oral contraceptives, by in-
creasing vitamin K-dependent cIotting fac-
tor activity, bring about an increase in
dosage of bishydroxycoumarin required for
desired anticoagulant effect. Administra-
tion of multimethylated xanthines is fol-
lowed by a decrease in pro thrombin time
in dogs receiving bishydroxycoumarin."
The need for an increase in dose of anti-
coagulant has been reported in patients
receiving methylxanthines.v"
Side effects of oral anticoagulants
Some of the additional effects of these
agents may be related directly or indirect-
ly to their primary mechanism of action in
suppression of synthesis of coagulation fac-
tors, while other actions appear entirely
unrelated. Several deserve considerable
further investigation because of potential
therapeutic utility.
Martius and Nitz-Litzowv-?" have shown
that very large doses of bishydroxycoumarin
inhibit oxidative phosphorylation. Phos-
phorylation appears to be inhibited at every
step in electron transport.": 39, H Phenin-
dione does not display this effect. Whether
this action is initiated through inhibition
of ubiquinone function or by means of
another mechanism is not yet cIear. No
decrease in oxidative enzyme activity is
demonstrable in the liver of anticoagulated
animals.
Coumarin derivatives display consider-
able antibacterial activity in vitro'": 66, 83,
168-170 which is thought to be related to
uncoupling of oxidative phosphorylation.v"
However, if bishydroxycoumarin-treated
rabbits are injected intracutaneously with
hemolytic streptococci, infection is more
extensive than that in controls.>" The
absence of fibrin in tissues of anticoagu-
lated animals has been proposed as the
factor contributing to increased spread of
infection.
Fontaine and colleagues'" have reported
that phenindione has an anti-inflammatory
effect equivalent to that of phenylbutazone
in rats with edema secondary to carageenin
injections in the foot pad, Other anticoagu-
lants are considerably less effective. A
similar effect can be demonstrated in ultra-
violet-induced erythema in guinea pig skin.
Of possible therapeutic potential is the
demonstration by a number of observers
of the benefioial effects of anticoagulants
in the reduction of spontaneous metastases
from malignant neoplasms. The effect of
anticoagulants on this phenomenon ap-
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pears to parallel the depression of pro-
thrombin activity. Cancer cells contain an
agent which induces fibrin formation.'!"
The presence of a microthrombus around
embolie tumor cells appears to contribute
to adherence and penetration of these
cells.!" In both transplanted and autoch-
thonous tumors in animals, adrninistra-
tion of anticoagulants brings about a
significant decrease in number and fre-
quency of spontaneous metastases."- 138, 139,
183 Since treatment with warfarin inhibits
the motility of cancer cells in vivo in
rabbit ear chambers, Thomes and asso-
ciates>" have proposed that the uncoup-
ling of oxidative prosphorylation might play
a role in the inhibition of motility; ad-
ministration of vitamin K1 res tores can-
cer cell motility. In addition, bishydroxy-
coumarin has a direct cytotoxic effect on
human cancer cells in vitro." Recently
Michaels'?" has reported a retrospective
study of cancer inciderice and mortality
rate in a group of 540 patients receiving
long-term oral anticoagulants for preven-
tion and treatment of thrombotic disease.
Incidence of cancer was comparable to
that predicted from statistics for that re-
gion. Eight deaths from cancer would
have been expected during the 1,569 pa-
tient-years of observation, while only one
was observed. Another patient who died
from an unrelated cause had hepatic
metastases from an undetected neoplasm
at autopsy. Although, as Michaels is aware,
the number of patients is too small for
demonstration of valid statistical differ-
ences, this study should provide the
stimulus for future prospective investiga-
tions.
Oral anticoagulants have also been used
as an. aid in the study of extramedullary
erythropoiesis. After carbon tetrachloride-
induced hepatic injury, mitotically active
hematopoietic cells of nonhepatic origin
localize in the liver, presumably trapped
in the liver by a fibrin network, a mecha-
nism similar to that thought to bring about
hepatic metastases of malignant neoplasms.
The administration of warfarin prevents
the development of these colony-forming
units; concurrent administration of vita-
min K1 restores to normal the number of
colony-forming units in the liver of mice
treated with CCl4 and warfarin. The au-
thors have questioned whether the estab-
lishment of hematopoietic colony-forming
units in "normal" sites of extramedullary
hematopoiesis, such as the spleen, might be
adversely affected by anticoagulants. l11
Additional pharmacologic actions have
also been described. Warfarin sodium has
bronchodilator activity, being about 50
per cent as active as aminophylline." On
swine coronary arteries both bishydroxy-
coumarin and warfarin have vasodilator
activity comparable to that of nitroglyc-
erin.P Bishydroxycoumarin in high con-
centration increases total coronary How in
the isolated perfused dog heart but also
has adepressant effect upon cardiac con-
tractile force and increases total myocardial
oxygen consumption; no effect could be
demonstrated with warfarin.F"
Phenindione has antithyroid activity in
rats, blocking uptake of p31 as effectively
as propylthiouracil.>" Other oral anticoagu-
lants do not display this effect which, with
phenindione, cannot be blocked by admin-
istration of vitamin K1 • The 48 hour p31 up-
take was at or below normal in five patients
receiving phenindione; uptake increased
after the drug was discontinued.
Both coumarin and indandione deriva-
tives (bishydroxycoumarin, 51 ethylbiscou-
macetate.>" and phenindionev'") have a
uricosuric effect, producing reversible im-
pairment of urate reabsorption by renal tu-
bules. Acenocoumarin and anisindione
have no appreciable uricosuric action.
Recently, Sekhar':" has reported that
diphenadione reduces serum cholesterol,
triglyceride and phospholipid levels, and
aortic plaque formation in atherosclerotic
cockerels and pigeons. Simultaneous ad-
ministration of vitamin K1 does not alter
this effect. George and associates'" have
shown that phenylindandione and phen-
procoumon accelerate clearing of p31 trio-
lein from the bloodstream.
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Drug
Coumarins
Bishydroxycoumarin
Ethyl biscoumacetate
Warfarin sodium
Cyclocumarol
Phenprocoumon
Acenocoumarin
Indandiones
Phenindione
Diphenadione
Anisindione
Usual loading dose
(mg. to 30%
prothrombin activity)
400- 700
1,800-3,000
30- 60
150- 400
18- 30
30- 60
400- 700
30- 60
250- 550
Usual daily
maintenance dose
(mg.)
25- 150
200-1,200
3- 15
25- 175
1- 6
2- 16
25- 200
3- 15
25- 200
Interval to
maximum effect
(hours)
36-72
18-36
36-72
24-48
36-72
24-36
24-36
60-84
24-48
Considerations in dinical management
Choice of drug; induction and main-
tenance dosage. Tahle I lists some of the
more commonly used oral anticoagulants
with ranges for usual loading and main-
tenance doses and times required to
achieve the desired increase in one-stage
prothromhin time, based upon our experi-
ence with these agents. Investigators, using
other criteria, have reported values which
differ from those in Table I. "Loading
dose" refers to the total dose of drug re-
quired to depress the Quick one-stage
prothromhin activity to a value less than
30 per cent. Time intervals are measured
to the peak effect rather than to the
first evidence of anticoagulant effect.
Ranges have been used hecause of the
marked interindividual variahility in re-
sponse.
Although much has been written about
choice of drug, other than for exclusion of
drugs hecause of toxic effects upon hema-
topoiesis, no single agent has been shown
to have characteristics which would justify
priority in clinical use. The most impor-
tant consideration is the experience a clini-
cian has had with the use of a particular
drug. From the point of view of cost,
bishydroxycoumarin is one of the least
expensive. A greater Huctuation in day-to-
day level of prothrombin activity has been
attributed to the shorter-acting drugs but,
if these compounds are administered more
frequently (e.g., a twice-daily dosage sched-
ule ), an impressive degree of stability can
be achieved." It has been proposed that
more potent drugs which have a lower
plasma concentration might display less
variation with respect to half-life 175; how-
ever, Solomon and Schrogiev" have not
been able to correlate marked differences
in individual response to a fixed dose of
hishydroxycoumarin with differences in
half-life of drug in plasma. Weiner!" has
proposed that longer-acting drugs can be
more readily managed if one gives a rela-
tively large intermittent maintenance dose
only after prothrombin activity increases
following the maximum depression from
the preceding dose. This presupposes that
the greater fluctuation in prothrombin ac-
tivity which is likely to occur with this ap-
proach does not contribute to a decrease in
therapeutic effectiveness.
Recently, O'Reilly and associatesv- have
suggested a different approach to the ini-
tiation of therapy. Rather than utilizing a
relatively large loading dose of drug (e.g.,
50 mg. of warfarin), they suggest con-
tinued administration of a moderate-sized
daily dose (e.g., 15 mg. of warfarin) until
prothrombin activity has reached the de-
sired level. As might be expected, this
means a greater delay before "therapeutic"
levels of prothrombin activity are achieved.
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However, they argue that this longer in-
terval reHects changes in the rate of de-
pression of factor VII activity while factors
II, IX, and X fall just as rapidly as with a
larger induction dose. They suggest that,
since these latter clotting factors may play
a greater role in stimulating propagation of
thrombus than does factor VII, the slower
depression of prothrombin activity by this
approach may be as satisfactory in pre-
venting further thromboembolism as the
more rapid depression achieved by the use
of larger initial doses. In our opinion, these
suppositions may be valid provided that
treatment with an oral anticoagulant is
accompanied by immediate and adequate
heparin therapy for at least five to seven
days while factors 11, IX, and X are slowly
decreasing.
In no other area of pharmacotherapy is
individualization more important than in
the administration of oral anticoagulants.
Some of the numerous variables which
may affect individual dosage requirement
have been discussed. We and many others
have noted as much as a tenfold interin-
dividual variation in dose of drug required
for maintenance of a stable depression of
prothrombin activity in patients being
treated for thrombotic disease. Other than
fundamental genetic differences in rates of
drug metabolism, age, sex, "body content'
of vitamin K, the presence of debilitating
disease which may affect hepatie function,
and intake of other "interacting" drugs ap-
pear to be the most common factors inHu-
encing this variability. In addition, oc-
casional patients with extensive thrombotic
disease may be unusually resistant.
Experience has shown that, regardless
of cause, many patients with pretreatment
prothrombin activity of less than 70 per
cent will display increased sensitivity to
oral anticoagulants. Smaller loading and
maintenance doses of drug should be
utilized for these patients. On the other
hand, as the usually sensitive seriously ill
.patient responds to therapy of his primary
disease (e.g., congestive heart failure),
daily maintenance doses of oral antico-
agulant may have to be increased several
fold to maintain a constant effect.
Combined use of heparin. As has been
mentioned, the maximum depression of all
of the four clotting factors known to be
affected by oral anticoagulants may not
be achieved until five to seven days after
the initial dose of drug. Although the rela-
tive influence of each factor in the promo-
tion of thrombus propagation in man is not
known, on the basis of experiments in ani-
mals, factors IX and X may be of particu-
lar importance. An increasing number of
clinicians have been extending the initial
period of combined therapy with both
heparin and an oral anticoagulant to a
minimum period of five to ten days. If
only short-term therapy (seven to ten
days) is planned, many are recommending
the use of heparin alone.
When both heparin and oral anticoagu-
lants are administered, blood for estima-
tion of one-stage prothrombin time must
be obtained at a time when residual
plasma heparin content has reached a low
level. Otherwise, the heparin in plasma
will bring about prolongation of prothrom-
bin time and thus prevent proper interpre-
tation of the effect of the oral anticoagu-
lant on clotting factor activity. This prob-
lem is a significant one when heparin is
given by subcutaneous injection. The most
practical method for simultaneous use of
these agents is the intermittent intravenous
injection of heparin at four- to eight-hour
intervals, the blood for determination of
prothrombin time being obtained just prior
to the next dose of heparin,
Laboratory control. All of the early and
many of the recent assessments of the
clinical efficacy of anticoagulants in the
treatment of thrombotic disease in the
United States have been based upon labo-
ratory control by the one-stage prothrom-
bin time of QUick.1 32 However, numerous
modifications of this procedure have been
devised and advocated as being "more ef-
fective" in control of anticoagulant ther-
apy, particularly in the reduction of
hemorrhagic complications. Some of the
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modifications which are most frequently
utilized include: (1) the Quick test with
the use of a BaS04-adsorbed plasma in
place of saline for determining dilution
curves-'"; (2) several modifications of the
Quick method determined on diluted
plasma'": 153; (3) the prothrombin and
proconvertin (P & P) test and its modi-
fications-'", (4) "thrornbotest'T"; (5) par-
tial thromboplastin times."
Each of these procedures has been pro-
moted with claims of greater sensitivity,
easier reproducibility, better standardiza-
tion, etc., but what has frequently been
ignored is that a given result by one
method is in no way comparable to the
result obtained when another technique is
used. The lack of equivalence of these
tests has been pointed out by a number
of observers.t'": 136, 137, 163. 181
Obviously, the optimal laboratory con-
trol of anticoagulant therapy should be
determined by that regimen which pro-
vides maximum protection against throrn-
boembolism while minimizing serious
hemorrhagic complications. While the
definitive answer to this problem has not
yet been provided, the best available data
have been derived from studies utilizing
the one-stage Quick prothrombin time.
The optimal range, as will be discussed
later, appears to be a prolongation of
Quick prothrombin time of between two
and three times the control value. This
range by the Quick method represents
more intensive anticoagulant therapy than
that recommended by the advocates of
either the P & P or thrombotest techniques.
As Miale':" points out, a prothrombin time
( Quick) of two and one-half times the
normal is equivalent to a value of 1 per
cent by the P & P method and 0.6 per cent
by the thrombotest. To date, there is no
evidence that any of the proposed modifi-
cations of the Quick procedure are superior
in the clinical management of patients as
assessed by the combined criteria of pre-
vention of thromboembolic and hemor-
rhagic complications of therapy at equiva-
lent levels of anticoagulation.
Although these tests are simple, con-
tinued supervision of personnel and
standardization of reagents are necessary
to assure reproducibility of results.':" The
tissue "thromboplastin" extracts show con-
siderable lability and variability and must
be carefully selected and repeatedly
checked. An understanding by the physi-
cian of the nature of the procedure and
methods of reporting results are critical to
proper interpretation and management of
the level of anticoagulant therapy. Results
have been reported as:
1. Pro thrombin time. The time for clot-
ting of anormal "control" plasma is re-
ported for comparison with that of the
patient's plasma.
2. Percentage prothrombin activity.
These percentage values are derived from
a curve made by testing various dilutions
of normal plasma with saline or BaS04-
adsorbed plasma. The dilution curve ob-
tained with saline differs from that ob-
tained with adsorbed plasma containing
additional factor V and fibrinogen. What
many physicians who administer antico-
agulants in their daily practice have failed
to understand is that this reported per-
centage value cannot be linearly related on
a percentage basis to the magnitude of
anticoagulant effect. The dilution curve is
hyperbolic in shape, a prolongation of a
few seconds in prothrombin time will be
reported as a large difference in percen-
tage, while in the therapeutic range, where
the slope of the curve changes, a con-
siderable increase in prothrombin time will
be reported as a very small change in per-
centage (Fig. 2). In managing therapy
one must know whether saline or adsorbed
plasma was used in preparing the dilution
curve; because of differing slopes of the
curve, a pro thrombin activity of 15 per
cent with adsorbed plasma is equivalent to
an activity of approximately 25 per cent
with the saline dilution curve.
3. Prothrombin index. This percentage is
derived by dividing the control prothrom-
bin time in seconds by patient's prothrom-
bin time and multiplying by 100. A pro-
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Fig. 2. Curve for Quick one-stage prothrombin activity (constructed from determinations of
"accelerated clotting time" of dilutions of normal plasma with saline).
thrombin index of 50 per cent is equivalent
to a prothrombin activity of approximately
20 per cent. The hazard is that misinter-
pretation of the prothrombin index as pro-
thrombin aetivity may lead the physician
to underestimate the oral anticoagulant
effeet and to administer more of the agent,
placing the patient in jeopardy of serious
hemorrhage.
Intensity and duration of therapy. Al-
though information comparing thrombo-
embolie eomplieation rates in patients
managed at differing levels of intensity of
therapy is searce, what information is avail-
able is in support of more intensive ther-
apy. In the antieoagulant treatment of
aeute myoeardial infaretion, the frequeney
of thromboembolie eomplieations was re-
dueed by about 40 per eent in those subjects
with prothrombin times maintained at or
above 25 seconds (about 23 per eent pro-
thrombin activity, Quick) as opposed to
those patients with less intensive treat-
ment.l'" In arecent randomized prospee-
tive study, patients with pulmonary em-
bolism alloeated to a group treated in the
10 to 29 per eent range of prothrombin
aetivity had a signifieantly lower ineidenee
of thromboembolie complieations during
therapy than those treated in a range of
30 to 49 per eent prothrombin activity
(Quick}." Sevitt and Innes,"!' in studying
incidenee at autopsy of thrombosis and
embolism in a group of injured patients
reeeiving prophylactie anticoagulants,
found a higher frequeney of thromboem-
bolie sequelae in those patients with a
Quick prothrombin time maintained at less
than twiee normal (prothrombin activity
of 24 per cent in their laboratory ).
Duration of antieoagulant treatment
must be related to type and severity of
Valume 11
Number3
Oral anticoagulants 325
thrombotie disease. However, as far as
venous thromboembolism is eoneerned,
our reeent experience with extending the
period of therapy by continuing treatment
on an outpatient basis has brought about
a significant reduction in rates of reeurrent
thromboembolism in those patients receiv-
ing more prolonged treatment. 37 Since anti-
coagulant therapy in outpatients must of
necessity be regulated with less frequent
labora tory measurements than those pro-
vided in ahospital environment,main-
tenance of prothrombin activity between
30 and 50 per cent is usually reeommended
to lessen the frequency of hemorrhagic
complications.
Same elinicians have proposed that,
when anticoagulant treatment is to be
terminated, the drug dosage be gradually
reduced to lessen the hazard of "rebound
thromboembolism." The validity of this
approach has never been doeumented. In
fact, the little re1iable data which are avail-
able da not support this premise.v?
Toxicity. In addition to hemorrhagic
complications, several eoumarin derivatives
have been shown to be associated on rare
oceasions with other side effects.':" Tran-
sient alopecia, severe dermatitis.t" skin ne-
crosis, and generalized urticaria have been
reported after ingestion of warfarin and
other coumarins. Ulcerations of the mouth
have appeared after administration of
acenocoumarin. Gastrointestinal distur-
bances (nausea, vomiting, diarrhea) ap-
pear rarely in association with bishydroxy-
coumarin or ethylbiscoumacetate therapy."
Taxie side effects have been reported
more frequently in association with use
of phenindione. These include agranulo-
cytosis, renallesions (albuminuria, poly-
uria, renal failure), dermatitis (including
exfoliative dermatitis), diarrhea and steator-
rhea, paralysis of accommodation and
blurring of vision, anemia, and hepatitis."'"
Bleeding. Same form of hemorrhage ap-
pears in approximate1y 10 per cent of
hospitalized patients receiving oral anti-
coagulants and in almost one in three indi-
viduals receiving lang-term therapy as out-
patients. The great majority of these epi-
sodes are minor and can be managed
without termination of treatment. Deaths
are rare. The apparent causes of hemor-
rhage are multiple and complex. Same of
the variables whieh may influence the
development of bleeding include: (1)
inordinate depression of clotting factor
activity; (2) a possible taxie effect upon
capillary walls; and (3) changes in plate-
let function. Since multiple coagulation
factars are depressed by oral anticoagu-
lants, efforts have been made to correlate
bleeding with selective depression of in-
dividual factars. Many conflicting reports
have appeared. Since after five to seven
days of treatment levels of activity of fac-
tors II, VII, IX, and X are markedly
decreased, the incrimination of any single
factor is difficult. Baugh13 has reported
that the levels of these factars are no
different in patients who are bleeding than
in those who are not.
When very excessive or lethai doses
of anticoagulant have been ingested by
animals'"- 95 or man,180 widespread dila-
tation of small blood vessels has been
noted. With one known exception.t'" no
histologie changes in the vessel wall it-
self have been detectable. An "increased
vascular fragility" has been postulated.w-
182 The petechiae which have been noted
in patients with coumarin overdosage
could be seeondary to the possible effects
of these agents on platelet adhesiveness
rather than to any structural alteration of
the vascular wall itself. The only evidence
for an alteration in vascular integrity is
the demonstration by Nelson'P that bis-
hydroxycoumarin increases the rate of
lass of T1824-labeled protein from the
bloodstream of rabbits.
Aseries of studies which may con-
tribute to our understanding of the patho-
genesis of bleeding are those performed
by Jaques74 in rabbits and rats. The inci-
dence of spontaneaus hemorrhage in an i-
mals receiving large doses of anticoagu-
lant alone is very low, However, if one
superimposes any other measure which
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affects another phase of hemostasis (plate-
lets, the vessel wall), the frequency of
lethai hemorrhage increases markedly.
Some of these other measures include ad-
ministration of p32, reserpine, steroids, or
production of "stress" (electric or insulin
shock, injection of formalin, sham opera-
tion, frostbite, etc.). Mortality rate from
hemorrhage increases with the increase in
hypocoagulability produced by the anti-
coagulant and with the increase in in-
tensity of the measure affecting another
phase of hemostasis. Unfortunately, since
so many factors may influence hemostasis
in anticoagulant-treated patients, the va-
lidity of this thesis is extremely difficult
to document in man, particularly the pos-
sible effects of "stress" upon the vascular
phase of hemostasis.
Since developments are relatively re-
cent, the quantitative role of drug inter-
action in the etiology of anticoagulant-in-
duced bleeding in man has also not yet
been adequately investigated. It appears,
however, that this factor may contribute
to an appreciable proportion of hemor-
rhagic episodes. MacDonald and Robin-
son'" have recently reported that in 14
of 67 episodes of bleeding, enzyme in-
duction was a contributing faetor; two
patients died. Forty of 52 patients with
myocardial infarction receiving anticoagu-
lants were also treated with barbiturates;
they required higher doses of anticoagu-
lants and therapy was more difficult to
control. Since barbiturates and other seda-
tives (chloral hydrate, glutethimide) are
administered so frequently, the majority of
reports of bleeding brought about by this
mechanism have been related to these
drugs. Enzyme induction by these seda-
tives brings about an increased rate of
metabolism of the anticoagulant and
necessitates an increase in the dose re-
quired to maintain the desired effect;
if the sedative is then discontinued the
prothrombin time will increase markedly
and bleeding may occur. Microsomal en-
zyme induction may appear within two
to seven days after administration of these
drugs4 0, 43 and may last for as long as
six weeks after therapy has been dis-
contlnued.v" The other forms of drug inter-
action act more directly to increase sensi-
tivity to anticoagulants.
In arecent survey of our experience
with anticoagulant therapy in 2,468 epi-
sodes of thromboembolism, bleeding oc-
curred in 7.9 per cent of the courses of
treatment. Major bleeding which was de-
fined as hemorrhage of such magnitude as
to require termination of anticoagulant
therapy appeared in 2.4 per cent; greater
than one half of these hemorrhagic events
were gastrointestinal in origin, followed
in order of frequency by vaginal bleeding,
hemorrhage from an operative wound, and
severe epistaxis, Minor bleeding, requiring
an adjustment in drug dosage without
termination of therapy, was present in the
remaining 5.5 per cent with the predomi-
nant source being the genitourinary tract
(hematuria) followed by epistaxis, minor
bleeding from a wound, vagina or gastro-
intestinal tract, ecchymoses, etc. About one
third of these episodes appeared to be
primarily related to associated heparin
therapy rather than to the oral anticoagu-
lant. Less frequently, bleeding may oc-
cur in brain and spinal cord, wall of the
intestine, pericardium, ovary, adrenal
glands, and other areas.P"
Bleeding usually occurs at values for
prothrombin activity by the Quick pro-
cedure of 15 per cent or below.v" Very
frequently, and particularly at higher pro-
thrombin activity, bleeding is related to
the presence of a pre-existing organic lesion,
On many occasions such lesions, especially
in the gastrointestinal tract, have been
previously unrecognized. Organic lesions
responsible for hemorrhage can be identi-
fied in at least one half of patients bleed-
ing at levels of prothrombin activity of 15
per cent or above.""
Reversal of anticoagulant effect. Vita-
min K1 (2-methyl-3-phytyl-1,4-naphtho-
quinone) corrects the abnormalities in
coagulation produced by oral anticoagu-
lants. An equimolar amount of vitamin
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K3 (2-methyl-l,4-naphthoquinone) is con-
siderably less effective, probably because
of its much more rapid conjugation and
excretion.?" When isotopically labeled vita-
min K1 is administered to anticoagulant-
treated rats, there is a positive corre1ation
between shortening of prothrombin time
and hepatic content of vitamin K1 . Since
vitamin K1 is metabolized very slowly, the
minimum effective dose of this agent
should be utilized if further oral anti-
coagulant therapy is contemplated; other-
wise, considerable resistance to the effect
of subsequent administration of anticoagu-
lant may be encountered, in same instances
for periods of several weeks or more. Ad-
ministration of doses of vitamin K1 of 2.5
to 5 mg., either orally or intravenously,
can have an appreciable effect in shorten-
ing a prolonged prothrombin time within
four to eight hours.?' Since recent studies
have shown a considerable interindividual
variability in response of prothrombin
times of warfarin-treated patients to small
doses of vitamin K1 (5 mg. or less),190 in
instances of life-threatening hemorrhage,
doses of 50 mg. will produce a more pre-
dictable response.v" Bleeding produced by
excessive dosage of anticoagulant is usu-
ally treated with a larger dose of vitamin
K1 than is bleeding secondary to unusual
sensitivity to an "ordinary" dose of drug.
In addition, the more prolonged the pro-
thrombin time, the larger the dose of vita-
min K1 needed for prompt reversal of ef-
fect. In the rare instance of very serious
massive bleeding, correction of coagulative
abnormalities can also be brought about
by administration of whole blood or
plasma.
Contraindications to anticoagulant ther-
apy. The decision to administer anticoagu-
lants must be made by balancing the risk
of serious or lethai hemorrhage against the
potential for equally morbid or fatal
thromboembolic disease. The hazard of
bleeding is especially great in patients
with other hemostatic abnormalities, recent
cerebral hemorrhage, recent operations
upon the central nervous system or eye,
or ulcerative lesions of the gastrointestinal,
respiratory, or genitourinary systems (e~­
pecially prostate gland). Of equal impor-
tance in contributing to an increased risk
of bleeding are an uncooperative patient,
inadequate laboratory control, and un-
informed or casual medical supervision.
Other entities which contribute to a higher
risk include severe hypertension, subacute
bacterial endocarditis, pericarditis, severe
hepatic disease, and certain nutritional
problems (particularly deflciencies of vita-
mins C and K). Many of these and other
contraindications which have been pro-
posed are relative rather than absolute. In
many instances anticoagulants can be ad-
ministered with relative safety (the risk of
serious bleeding being less than the hazard
of fatal thromboembolism) if dosage is
carefully managed and laboratory control
is rigidly supervised.
Some indications for therapy. Only the
more important indications and a few of
the clinical trials will be noted. By far, the
most important indication for anticoagu-
lant therapy, in terms of both numbers of
patients and value, is the prevention and
treatment of deep venous thrombosis and
pulmonary embolism. Since numerous stud-
ies have pointed out the extreme difficulty
in clinical recognition of venous throm-
boembolism, prophylaxis will be superior
to therapy of established disease in the
prevention of morbidity and death. The
many diseases associated with an increased
risk for development of secondary throm-
boembolic disease and the case for much
more extensive use of prophylactic anti-
coagulants in patients confined to bed with
these conditions have been repeatedly
emphasized."- 35, 148 A number of trials
have shown that anticoagulants can bring
about a reduction of up to tenfold in the
incidence of thromboembolism in high-risk
patients with obstetrical and surgical prob-
lems."- 49, 141, 149 A signiBcant decrease in
lethai thromboembolism is also achieved
when anticoagulants are administered to
patients with congestive heart failure.'
Numerous trials of anticoagulants in the
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treatment of clinically established venous
thrombosis and pulmonary embolism have
provided data which, when compared by
retrospective analysis with prior series of
patients treated by bed rest alone, sub-
stantiate the significant contribution of
anticoagulants to the reduction of mor-
bidity and death from this disease. How-
ever, it was not until 1960 that the first
adequately designed randomized prospec-
tive clinical trial of anticoagulants in the
treatment of pulmonary embolism was re-
ported by Barritt and Jordan.1 2 By the
time 19 patients had been followed in the
control group (bed rest alone) and 16 in
the treated group, five control subjects had
died from pulmonary embolism and five
others had developed nonfatal pulmonary
emboli, while none of the treated patients
had any evidence of recurrent disease (p
< 0.001). A comparable controlled trial
of treatment of deep venous thrombosis
alone has not yet been performed, but
morbidity and death in anticoagulant-
treated patients is so low as to leave little
doubt regarding its value."
The value of anticoagulants in the treat-
ment of acute myocardial infarction is
much more controversiaI. Despite alI the
recent debate concerning selection of pa-
tients and the influence of multiple other
variables, the summary by Douglas-? of
the more important clinical trials indicates
a 50 per cent over-all reduction in mortal-
ity rate for treated patients as compared
to that for control patients. With the ad-
vent of coronary care units, the current
aggressive attitude toward prevention and
treatment of arrhythmias and earlier mo-
bilization of the patient, the reduction in
mortality rate brought about by antico-
agulants may be considerably less in fu-
ture trials. Many investigators believe that
whatever reduction in mortality rate is
achieved may be related less to a decrease
in deaths from extension of the myocardial
infarct or recurrent infarction than to a
decrease in incidence of fatal pulmonary
embolism.
Although many studies have supported
the long-term use of anticoagulants (one
year or more ) in lowering the incidence of
recurrent myocardial infarction,"- 100, 173 a
well-controlled recent investigation>" has
not provided support for their use; in that
study, however, the prothrombin and pro-
convertin (P & P) test was utilized and
the intensity of treatment was moderate
(only 13 per cent of P & P values below
30 per cent, about 50 per cent by the Quick
method ). As Loeliger and associates'"
have recently demonstrated, the intensity
of anticoagulant treatment may be the crit-
ical factor in achieving a significant reduc-
tion in morbidity and death; in a double-
blind clinical trial, rigorously controlled
anticoagulant therapy brought about a sig-
nificant reduction in incidence of cardio-
vascular deaths.
The validity of anticoagulant therapy in
the management of severe angina pectoris
and "impending myocardial infarction" is
also difficult to assess. True randomization
of patients has not been carried out. Sever-
al groups have reported an appreciable
reduction in frequency of myocardial in-
farction particularly within the first few
months of initiation of therapy.v» 185
One point of general agreement has been
reached concerning the use of anticoagu-
lants in cerebrovascular disease. Antico-
agulants have no place in the treatment
of acute completed strokes and may actu-
ally be harmful by increasing the risk of
fatal cerebral hemorrhage. In addition,
there is no unequivocal evidence that long-
term anticoagulant therapy favorably in-
fluences the incidence of recurrent cerebral
infarction although McDevitt and Mc-
Dowell'" have recently reported that anti-
coagulant-treated patients had a lesser
morbidity and mortality rate within the
first year after a completed stroke. Al-
though the data are by no me ans defini-
tive, several trials provide some evidence
that antieoagulants may be of value in re-
ducing the extent of neurologie deficit in
patients with "stroke in evolution.T'?- 26 As-
sessment of the value of these drugs in
"transient ischemic attaeks" is partieularly
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difficult because of problems of aecurate
diagnosis and the variability in frequency
and severity of attacks. Nevertheless, a
number of observers,": 56, 155 including a
large cooperative study," have reported a
reduction in frequency of attacks in pa-
tients receiving anticoagulants.
Although no controlled prospective tri-
als have yet been condueted, long-term
anticoagulant therapy appears to be of
benefit in patients at risk from arterial em-
bolism, including cerebral embolism. The
subjects at particular risk are those with
mitral stenosis and atrial fibrillation seeon-
dary to rheumatie heart disease. Several
observers have reported a reduetion in fre-
queney of arterial embolism of the order of
tenfold during periods of antieoagulant
treatrnent.v- 96, 126 A delay of several days
or more before initiation of antieoagulants
in patients with reeent cerebral emboli
may be prudent in order to reduee the risk
of hemorrhage into an infarcted area.
Similarly, the prophylaetie value of anti-
eoagulant therapy in patients undergoing
eardioversion and in those with prosthetie
heart valves is difficult to assess but seems
established.v " In the former group there
is a statistically valid deerease in the fre-
queney of embolie episodes oeeurring be-
tween six hours and six days after eon-
version.?"
The use of anticoagulants has been ad-
voeated in the management of athero-
sclerotie peripheral arterial disease and in
retinal arterial and venous thrombosis, but
no clear evidenee of benefit has yet been
presented.
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